Theconcept of microbiome-based therapeutics has generated significant enthusiasmwithin the medical science community, defining a new frontier in the field ofmedicine. Despite having captured the interest of several venture capital firmsand big pharma players, no microbiome-based therapeutic has been officiallyapproved by an authorized medical product regulator. However, the current developmentpipeline of microbiome therapeutics has several promising candidates that arelikely to result in commercial success stories soon.
To order this 640+ page report, which features 235+ figuresand 275+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
The USD 4 billion (by 2030) financial opportunitywithin the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, hasbeen analyzed across the following segments:
§ Type of Therapy (Tx)
§ Prescription Drug
§ Prebiotics
§ Probiotics
§ Type of Molecule (Tx)
§ Small Molecules
§ Biologics
§ Target Indication(Tx+Dx)
§ Acne Vulgaris
§ Atopic Dermatitis
§ Clostridium difficileInfection
§ Colorectal Cancer
§ Crohn’s Disease
§ Diabetes
§ Irritable BowelSyndrome
§ Lactose Intolerance
§ Lung Cancer
§ Nonalcoholicsteatohepatitis (NASH)
§ Obesity
§ Ulcerative colitis
§ Therapeutic Area (Tx+Dx)
§ Autoimmune Disorders
§ Dental Disorders
§ Digestive andGastrointestinal Disorders
§ DermatologicalDisorders
§ Infectious Disease
§ Metabolic Disorders
§ Oncology
§ Others
§ Key Geographical Regions(Tx+Dx)
§ North America
§ Europe
§ Asia-Pacific and Restof the World
The Human Microbiome Market, 2019-2030 report features thefollowing companies, which we identified to be key players in this domain:
§ 4D Pharma
§ ArmataPharmaceuticals
§ Evelo Biosciences
§ Rebiotix (Acquired byFerring Pharmaceuticals)
§ Seres Therapeutics
§ Vedanta Biosciences
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Microbiome Therapeutics: Market Landscape
5. Company and Drug Profiles
6. Microbiome Diagnostics: Market Landscape
7. Fecal Microbiota Therapy (FMT)
8. Attractiveness Competitiveness (AC) Matrix
9. Microbiome Related Initiatives of BigPharmaceutical Players
10. Start-up Health Indexing
11. Key Therapeutics Areas
12. Funding and Investment Analysis
13. Contract Services for Microbiome Therapeutics
14. Big Data and Microbiome Therapeutics
15. Microbiome Therapeutics: Market Forecast andOpportunity Analysis
16. Microbiome Diagnostics: Market Forecast andOpportunity Analysis
17. Fecal Microbiota Therapies: Market Forecast andOpportunity Analysis
18. Case Study: Microbiome-based Products in OtherIndustries
19. Concluding Remarks
20. Executive Insights
21. Appendix I: Tabulated Data
22. Appendix II: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
